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Abstract
Introduction: Electronic health records provide an unparalleled opportunity for the use of patient data that is routinely
collected and stored, in order to drive research and develop an epidemiological understanding of disease. Diabetes, in
particular, stands to benefit, being a data-rich, chronic-disease state. This article aims to provide an understanding of the
extent to which the healthcare sector is using routinely collected and stored data to inform research and epidemiological
understanding of diabetes mellitus.
Methods: Narrative literature review of articles, published in both the medical- and engineering-based informat-
ics literature.
Results: There has been a significant increase in the number of papers published, which utilise electronic health records as
a direct data source for diabetes research. These articles consider a diverse range of research questions. Internationally, the
secondary use of electronic health records, as a research tool, is most prominent in the USA. The barriers most commonly
described in research studies include missing values and misclassification, alongside challenges of establishing the
generalisability of results.
Discussion: Electronic health record research is an important and expanding area of healthcare research. Much of the
research output remains in the form of conference abstracts and proceedings, rather than journal articles. There is
enormous opportunity within the United Kingdom to develop these research methodologies, due to national patient
identifiers. Such a healthcare context may enable UK researchers to overcome many of the barriers encountered elsewhere
and thus to truly unlock the potential of electronic health records.
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Introduction
The expansion in use of electronic health records
(EHRs) provides an unparalleled opportunity for the
use of routinely collected patient data to drive research
and deliver an epidemiological understanding of the
basis of disease. Whilst some challenges exist around
legal, ethical and technological issues,1 there is an
increasing number of studies using EHRs to deliver
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meaningful research outputs.2 These studies are some-
what sporadic, in diverse specialist areas including
chronic obstructive pulmonary disease3 and heart fail-
ure research.4,5 Additionally, there are published opin-
ion pieces highlighting the potential importance the use
of EHRs in research.6
An EHR can be defined as ‘a repository of patient
data in digital form, stored and exchanged securely,
and accessible by multiple authorised users. It contains
retrospective, concurrent, and prospective information
and its primary purpose is to support continuing, effi-
cient and quality integrated health care’.7 Whilst there
is a myriad of different definitions applied to EHRs,8
this represents a widely accepted and comprehensive
definition.9 Critical to this paper is that an EHR’s pri-
mary purpose is the provision of healthcare. Use of the
information routinely collected and stored for the pur-
poses of research is a secondary use of these EHRs.
This paper is specifically looking at the direct second-
ary use of these EHRs as research tools. By direct use,
we are looking at instances where research teams have
taken data directly from the clinical EHR, rather than
indirect uses where multiple EHRs from different sour-
ces have been combined together (often with anonym-
isation or pseudo-anonymisation) into registries or
similar repositories. The consideration, specifically of
direct secondary uses, is important as it represents an
assessment of what immediately can be achieved from
data we already have, rather than data requiring third-
party processing, complex information governance
arrangements and often payment. Neglecting these
existing real-life data sources would represent waste
of a ready and potentially valuable resource.
The first EHR was created by Loughead Aircraft
Manufacturing Company (better known as Lockheed
Martin Aerospace) in the 1960s, alongside a small
number of other pioneer academic groups. Wider
adoption of EHRs only began with commercialisation
of systems in the 1990s.10 Use, in the UK, was some-
what delayed; potentially due to the absence of com-
mercial market forces in the National Health Service
(NHS), yet the UK now represents the largest EHR
market in Europe.11
The wider uptake of high quality EHRs has been
fuelled by government and trans-national initiatives,
including the $19 billion HiTECH Act in the USA12
and e2 billion Innovative Medicines Initiative in the
European Union.13 There is, however, significant geo-
graphic variation in the adoption and approach to
EHRs, with some countries (notably Denmark and
Sweden) utilising national EHRs and other countries
(the USA and UK) adopting organisation spe-
cific EHRs.14
Diabetes represents a truly data rich pathology with
a wealth of routinely collected data, including but not
limited to; average blood glucose, foot health, eye
health, cardiovascular health and renal health.
Diabetes therefore represents a pathology particularly
able to benefit from the use of EHRs in research.
Diabetes further represents a critical international chal-
lenge with a global prevalence that has doubled since
1980 from 4.5 to 7.8% of the adult population.15
Developing and exploiting new data and information-
driven research methods is therefore essential to tack-
ling this emerging global burden. At the time of writing
this paper, no review has been performed to identify
what has been achieved through EHR-based diabetes
research, how that progress has been achieved or an
appraisal of such studies.
This work represents first a review of the direct use
of EHRs as a research tool in diabetes. It considers
current applications, barriers and future strategies. It
also provides a meaningful benefit by developing an
understanding of where gaps currently lie in the
research literature, and how we can approach and over-
come challenges to EHR research.
Methods
Prospective registration
This review was prospectively registered with the
PROSPERO database (registration number:
CRD42016038550). PROSPERO is an ‘international
database of prospectively registered systematic reviews
in health and social care, welfare, public health, educa-
tion, crime, justice, and international development,
where there is a health-related outcome’.16 The
system is supported by the University of York and
aims to both reduce duplication of research and
avoid bias. All registered trials undergo a review pro-
cess prior to acceptance.
Search strategy
This review is underpinned by a comprehensive search
strategy including MEDLINE, Embase and
Engineering Village databases. Whilst Medline repre-
sents an important source of medicine, nursing and
pharmacy literature, it is also important to include
Embase in such a study, based on its coverage of phar-
macological articles. The OVID search platform allows
both Embase and MEDLINE to be searched simulta-
neously. In addition, informatics and computer systems
engineering approaches have been particularly relevant
to EHR research, and for a truly comprehensive search
strategy, it is therefore necessary to consider a search of
the relevant engineering literature in this review. The
Engineering Village search platform comprises 12 sep-
arate databases including Ei Compendex, Inspec,
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GEPBASE, GeoFef, US Patents, NTIS,
EnCompassLIT, EnCompassPAT, PaperChem,
CBNB and Chimica. Combining both the OVID and
Engineering Village search platforms adequately and
comprehensively covers the relevant medical and engi-
neering literature.
The search included only English language papers,
published between 2006 and June 2018. This is appro-
priate to the time period, for which there has been the
existence of meaningful high-quality EHRs within clin-
ical systems. Whilst it could be argued to include a five
year cut off, there is a risk this would unintentionally
exclude the earliest secondary research uses of EHRs,
which could be of significant value and interest. This
study focused solely on original research articles,
matching our aim to identify more specifically what
original research has been performed using EHRs as
a direct research data source.
There is an important need to consider the extent to
which the grey literature should be incorporated within
this study methodology. A natural concern with the
application of the grey literature is the variability of
study quality and absence of peer review. Given the
risks of bias associated with inappropriately dealing
with large data-sets contained within EHRs,17 a con-
sideration of the grey literature is not included here.
There remains contention as to a formal definition of
‘grey literature’, with some authorities including and
others excluding published conference abstracts.18
Conference abstracts can be important to demonstrate
early and developing research, as well as research that
has not progressed to publication. Such information is
therefore valuable to this review, and published confer-
ence abstracts indexed in the databases searched are
included within the review.
Search terms. ‘Electronic health record(s)’ or ‘Electronic
Patient Record(s)’ OR ‘Electronic Medical Records’
and ‘diabetes’ were the key search terms employed.
‘Electronic Health Records’ is the relevant NIH
MeSH term, however the other search terms are includ-
ed to ensure a comprehensive search. There was no
attempt to distinguish Type 1 from Type 2 diabetes;
not only can these be poorly recorded in EHRs19 but
also the data variables available in EHRs are usually
applicable to both.
Research studies that do not explicitly use EHR
data, as a direct research data source, are excluded.
In pilot work for this study, the following types of
study were identified that would need excluding: studies
where a separate research data registry is created, usu-
ally through manual inputting of data;20 research
where the EHR is used solely for patient recruitment/
identification;21 and research where a health record
database is created solely for research purposes.22
Whilst excluded from this study, these approaches are
themselves interesting and could potentially form the
future bases of additional research reviews.
Papers were selected by initially screening article title
and article abstract. Those papers identified as relevant
were subject to a second stage of screening through
review of the whole article. Inclusion criteria
(Table 1) represent English language articles, published
in the last 10 years, applying an interrogation of EHR
data to answer a specific medical research question.
Papers specifically considering the design/formatting
of EHRs and the use of EHRs for operational manage-
ment, rather than clinical research purposes, will also
be excluded.
Data, extracted from included papers, were struc-
tured according to a pre-defined and piloted proforma
that incorporated: year of publication, number of
unique patient records extracted, country of publica-
tion, type of research question, primary/secondary
care, single centre/regional/national data source,
whether barriers are discussed and whether opportuni-
ties for further research are discussed. Under each of
these headings further information has been extracted
for the narrative of the clinical review. Definitions cov-
ering the type of research question are included in
Table 2; studies can belong to multiple categories.
Meta-analysis was not performed.
Results
Initial search
The search strategy identified 703 research papers
meeting the inclusion criteria form the Medline and
Embase searches, with 268 papers from Engineering
Table 1. Inclusion and exclusion criteria.
Inclusion criteria Exclusion criteria
Registry data-based studies
EHRs used solely for patient
identification/recruitment
Research generated database
English language Non-English language studies
Studies from
1 Aug 06 onwards
Studies prior to 1 Aug 06
Human Non-human studies
Adult (over 18) Non-adult studies (under 18)
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Village. This resulted therefore in a total initial search
of 971 papers.
Paper selection
Individual review of articles by title, abstract and full
paper resulted in exclusion of 589 articles (84%) from
the OVID/Embase search; 114 articles were taken for-
ward for further study and data extraction; 8 articles
were unobtainable from the research literature and
excluded from the study. The reasoning for papers
being excluded is included in the flowchart in Figure 1.
Review of the articles extracted from the
Engineering Village search resulted in exclusion of
230 papers (86%), for the reasoning demonstrated in
Figure 2. There were 38 papers identified that met the
aims/objectives of this study,23,24 however 2 of these
had been identified in the OVID/Embase search and
were already included within the study. This resulted
in a total collection of 150 papers selected for further
analysis. It should be noted that, whilst the exclusion
rate of papers from the Engineering Village search was
high, there was substantial content of interest and rel-
evance to clinical research despite this being a rarely
used resource. The articles, whilst not relevant for this
study, focused on the design, operation and implemen-
tation of EHR systems, or of clinical systems in general
and their overall impact on clinical care. We would
strongly argue that greater exposure and awareness of
this valuable resource is important for future clinical
researchers in healthcare research.
Data analysis
Publication trends over time. Over the 12-year period of
study, 150 original research articles were identified. The
distribution of publications over time is demonstrated
in Figure 3. It is clear that there is a notable step-
change in publication numbers occurring around 2012.
Sample size. The largest sample size identified was 4.1
million patients, whilst the smallest was 30 patients.
The mean average number of patients per study was
99,757, whilst the median average was 3352. It is
important to note, therefore, that there is the potential
for these averages to be distorted by outlying values, in
particular, large value outliers. There is no clear
Table 2. Definitions relating to study research questions.
Term Definition
Epidemiology Papers relating to the incidence, prevalence or distribution of diabetes included asso-
ciations with other diseases
Prevention Papers relating to the prevention of Type 2 Diabetes Mellitus (T2DM), including pre-
diabetes states
Susceptibility Papers identifying risk factors for the development of diabetes
Diagnosis Papers focusing on the diagnosis of Type 1 Diabetes Mellitus (T1DM) or T2DM
Prognosis Papers focusing on the prognosis of diabetes populations either with or without
complications
Complications Papers considering complications of diabetes, their diagnosis, epidemiology
and treatment
Medication treatment Papers considering the benefits of medication treatment, or comparing medications for
patients with diabetes
Medication Side Effect Papers considering side effects of medications used to treat diabetes or diabetic
complications
Non-pharmacy intervention Papers considering non-medication-based intervention for the treatment of diabetes and
its complications
Insurance based Papers focusing on health insurance based issues for patients with diabetes
Service delivery Papers focusing on the delivery of care of individuals or populations with diabetes
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temporal trend to median sample sizes over time as
demonstrated in Figure 4 (all sample sizes included).
Location of research. English language, original research
articles, which met the inclusion criteria, were identified
as originating from 17 different countries. One study
represented an international study, utilising electronic
health data from both the UK and Canada.25 The larg-
est number of studies originated from the USA (74
studies) with 39 studies from the UK. A full breakdown
considering the number of studies per country is dem-
onstrated in Figure 5.
Type of publication. Seventy-four articles (49%)
extracted from the bibliographic databases were con-
ference proceedings or conference abstracts.
For studies originating from the UK 77% were pub-
lished conference abstracts or proceedings. This is in
comparison to only 40% of US studies being published
as conference abstracts. This is a finding of some sig-
nificance and is discussed below.
Nature of articles. Articles were identified for each of the
pre-specified study categories: epidemiology, preven-
tion, susceptibility, diagnosis, prognosis, complica-
tions, medication treatment, medication side effect,
OVID / Embase search  
strategy results
(n = 703)
Articles after duplicates 
removed (n = 629) 
Articles after 
unobtainable papers 
removed 
(n = 621)
Duplicates excluded: 
(n = 74)
Articles unobtainable 
after exhaustive search 
(n = 8)
Articles meeting 
eligibility criteria
(n = 114)
Articles excluded based on eligibility criteria (n = 507) 
Not use of EHR as a data source (n = 205) 
Not focused on diabetes mellitus (n = 291) 
Not adult study population (n = 17) 
Not original research articles (n = 23) 
NB: Some articles excluded based on multiple criteria 
114 articles selected  
for further study
Figure 1. Flow chart demonstrating assessment of articles for inclusion from OVID/Embase search.
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non-pharmacy intervention, service delivery, insurance
based. Many articles covered multiple categories. The
most common study purposes were to investigate com-
plications (50 articles), epidemiology (34 articles) and
diabetes complications (30 articles).
There was considerable variation in the sample sizes
used for each of the study types. The median average
number of patients, in studies considering medication
treatment was 7454, compared to 1861 patients for dia-
betes complication studies and 12,673 for epidemiology
focused studies.
Engineering village 
search strategy results
(n = 268)
Articles after duplicates 
removed (n = 232) 
Duplicates excluded: 
(n = 36)
Articles meeting 
eligibility criteria
(n = 38)
Articles excluded based on eligibility criteria (n = 194) 
Not use of EHR as a data source (n = 105) 
Not focused on diabetes mellitus (n = 69) 
Not original research articles (n = 21) 
Not English language (n = 1) 
Not Adult population (n = 1) 
Article not found (n = 1) 
NB: Some articles excluded based on multiple criteria 
38 articles selected  
for further study
Figure 2. Flow chart demonstrating assessment of articles for inclusion from Engineering Village search.
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Figure 3. Article publication numbers by year.
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Figure 4. Median sample size by year.
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Discussion
Current extent of secondary use of EHRs in
diabetes research
This study identifies a number of publications and
research outputs that describe the secondary use of
EHRs in diabetes research. The number of publications
has increased over time, with a step-change in 2012,
which we would argue coincides with the increased
commercialisation and wider adoption of EHR systems
following the US HiTech Act and EU Innovative
Medicines Initiative. Since 2012, however, the number
of publications has plateaued, perhaps in contrast with
medical publication numbers in general, which contin-
ue to increase at a near exponential rate. It is clear,
therefore, that there are barriers restricting the wider
adoption and exploitation of EHR research methodol-
ogies, which must be addressed.
The UK’s adoption of EHRs as a research tool in
diabetes in particular is embryonic, with the vast
majority of publications being conference abstracts.
The failure to convert these conference abstracts to
full publications could suggest barriers exist to full
publication, limitations to existing EHR datasets, or
non-specialist researchers experimenting with
EHR research.
Internationally, we would argue the potential of
these research approaches is evident, with large
sample sizes, across multiple centres, tackling a diverse
range of research questions. There is the clear ability to
adapt sample sizes to the research question under study
with epidemiological studies frequently utilising the
largest cohort numbers.
A particular challenge to the US studies that cur-
rently dominate the published literature are the
insurance-based models and data restrictions that
exist within such insurance-based healthcare systems
and datasets. We might argue that some commercial
US healthcare EHRs are designed to have insurance
and billing structures,28 with patient care a subsequent
(or secondary) addition, and therefore, in effect,
making the extraction of data for research purposes a
tertiary use.
Barriers to diabetes research
Approximately half of studies reported barriers or lim-
itations, as a result of using EHR data. Many studies
reported multiple limitations; many conference
abstracts however were brief and did not outline limi-
tations. The most commonly reported limitation was
that of missing data values,29 examples include failures
to record whether glucose values were fasting or
random30 and limited information on diabetes-specific
outcome measures such as foot amputation31 or cause
of death in the community following hypoglycaemia or
diabetic ketoacidosis.32
Limited information on medication compliance was
frequently described as a barrier,33–35 this is particu-
larly significant given the high proportion of studies
focused specifically on medication treatment in diabe-
tes. Problems with misclassification of diabetes, and
difficulty distinguishing between type 1 and type 2 dia-
betes were also described.36,37 Only two studies
reported problems with data extraction, namely the
extraction of unstructured data26 and procedural var-
iations in the documentation of information.27 There
were, however, concerns regarding a lack of longitudi-
nal data in certain EHRs and fragmentation of patient
data across diverse EHRs.30,31 These data fragmenta-
tion and longitudinal concerns were more prominent in
US studies, rather than UK studies, which would be
expected from the nature of NHS records; however,
without a single national EHR there will remain prob-
lems, despite all patients having a single national iden-
tifier number (NHS number).
It is important to note the high proportion of
extracted articles that were conference proceedings,
rather than journal articles, and to consider this as a
barrier in itself. This is despite a wide range of impor-
tant topics and meaningful findings discussed within
these articles. This could represent barriers such as a
lack of funding available to develop these research
projects into substantial pieces of work sufficient for
peer-reviewed journal publication, or a lack of suitable
journals accepting such articles for publication.
Whatever the reason for a failure to translate such
research into full papers represents a barrier to the
wider adoption of usefulness of EHR research, it is
interesting that this was a particular barrier in the
UK, and suggests that we continue not to utilise fully
0 10 20 30 40 50 60 70 80
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Mexico
Canada
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Figure 5. Country of origin of research articles.
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at a system level, the important information held
within our EHRs.
Future opportunities for EHRs in diabetes research
There are clear opportunities that could overcome
some of the challenges described above. Excitingly,
the UK has now moved on from the failed NHS
National Programme for IT, becoming the largest
EHR market in Europe.11 This offers the exciting
potential to overcome key barriers, most particularly
that of generalisability. Many of the current EER-
based studies are limited by being only single-centre
studies or based on small regions. The UK healthcare
system has the significant advantage of every member
of the population having a unique patient identifier,
which enables larger-sized studies and helps avoid
some of the barriers generated by missing patient
values or misclassifications as patients move between
providers or re-present.
Limitations of this study and further work
This study has a number of limitations. First, it repre-
sents a narrative review without formal independent
two-author article identification, extraction and analy-
sis. Whilst a meta-analysis would be inappropriate
given the diversity of the study designs and methodol-
ogies, a more systematic two-author approach to arti-
cle selection and data extraction could be argued to
improve the quality of the study. Importantly though,
this study did undergo prospective PROSPERO regis-
tration, with a pre-defined and piloted data collection
tool. In the context of the first review of its kind, the
study still has significant potential to add learning to
the research literature and should be considered as an
exploratory review in an underexplored area on which
future research can build.
Restrictions also limited this paper to considering
only English language journals, it is certainly likely
that EHR datasets internationally have been adopted
for research purposes published in other languages – in
particular from Asia, South America and Northern
Europe. This review excluded the grey literature. It is
evident from the articles extracted and references pro-
vided that a number of consultancy firms and charities
have utilised EHR data and may not have published
their work in academic journals. Finally, restrictions
were placed on the definition of secondary use of
EHRs, excluding registries and the use of EHRs for
recruitment to clinical studies. Both these areas repre-
sent important research areas, and further study to
understand the contribution of EHRs to these fields
would be beneficial.
Further research is needed to look beyond simply
diabetes and compare the approaches taken in other
clinical specialities. The understandings developed for
diabetes here might not be generalisable across disease
processes. Indeed, in the increasing trend for medical
research to occur within speciality ‘siloes’ there is the
exciting potential for EHR-based research to cross and
unite research teams.
Conclusions
There is clearly an established body of research that
utilises EHRs as a data source for diabetes research.
This research covers a broad range of research ques-
tions. The published studies often include large data
sets but are limited by missing values (many specifically
required for diabetes related research) and challenges
of generalisability. The small number of journal articles
published using UK data suggests research of this
nature is only in its infancy in the UK. The UK how-
ever represents an exciting and almost unique environ-
ment for such research, with national unique patient
identifiers allowing for large multi-centre sample sizes
overcoming challenges of generalisability and maximis-
ing the clinical usefulness of results.
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